ACOG vs. ATAI, RVNC, PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, and FHTX
Should you be buying Alpha Cognition stock or one of its competitors? The main competitors of Alpha Cognition include Atai Life Sciences (ATAI), Revance Therapeutics (RVNC), Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.
Alpha Cognition vs.
Alpha Cognition (NASDAQ:ACOG) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.
Alpha Cognition's return on equity of 0.00% beat Atai Life Sciences' return on equity.
Atai Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 352.26%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Atai Life Sciences is more favorable than Alpha Cognition.
In the previous week, Atai Life Sciences had 6 more articles in the media than Alpha Cognition. MarketBeat recorded 6 mentions for Atai Life Sciences and 0 mentions for Alpha Cognition. Atai Life Sciences' average media sentiment score of 0.66 beat Alpha Cognition's score of 0.00 indicating that Atai Life Sciences is being referred to more favorably in the news media.
Alpha Cognition has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
Atai Life Sciences received 333 more outperform votes than Alpha Cognition when rated by MarketBeat users.
28.4% of Atai Life Sciences shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Alpha Cognition has higher earnings, but lower revenue than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.
Summary
Atai Life Sciences beats Alpha Cognition on 10 of the 15 factors compared between the two stocks.
Get Alpha Cognition News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACOG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Cognition Competitors List
Related Companies and Tools
This page (NASDAQ:ACOG) was last updated on 2/22/2025 by MarketBeat.com Staff
